dm+d

35299711000001103

Articles

Medicines that are considered safe for use in the acute porphyrias

29 May 2020The UK Porphyria Medicines Information Service (UKPMIS) and Cardiff Porphyria Service produce a list of medicines that are considered to be safe for use in…
Search Articles

Refrigerated Storage

FasenraAstraZeneca

AstraZeneca
Fasenra
30 mg solution for injection in pre filled syringe

In the event of an inadvertent temperature excursion the following data may be used:
The product is stable when exposed to a single temperature excursion of 0°C to 2°C for a maximum of 24 hours or 8°C to 40°C for a maximum of 24 hours.

When exposed to excursions falling within these parameters, the item can be returned to the recommended storage conditions of 2-8°C and no change in expiry date is required.

Healthcare professionals should contact AstraZeneca Medical Information on an individual basis if the excursion falls outside of the durations and temperature ranges specified above.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

No
Yes
25 March 2021
London MI Service

New Medicines

FasenraSevere bilateral chronic sinusitis with nasal polyps in patients who are symptomatic despite standard therapy

Information

Fasenra
Licence extension / variation
AstraZeneca
MedImmune

Development and Regulatory status

None
Phase III Clinical Trials
Pre-registration (Filed)
Sep 21According to the company ´s latest annual report, EU filing is planned for 2022 [8].
Jul 21Currently pre-registration in the US [6].
Mar 21Following an update from the company that market benralizumab, NICE will not be progressing with its scoping exercise at this stage. Latest plans for UK availability are unknown [7].
Sep 19Filings will be in 2021 [3].
Sep 18Filings based on OSTRO study planned for 2020 or later [2].

Category

Monoclonal antibody binding to the interleukin-5 receptor that depletes eosinophils
The population prevalence of nasal polyps is reported as 2-4%, with no racial predilection. The male to female ratio has been reported at approximately 2:1
Severe bilateral chronic sinusitis with nasal polyps in patients who are symptomatic despite standard therapy
Subcutaneous

Further information

Yes

Trial or other data

Sep 20Both co-primary endpoints of reduced nasal polyp size and blockage met in PIII OSTRO trial in patients with chronic rhinosinusitis with nasal polyps [5]
Oct 19Recruitment completed for the OSTRO trial. Estimated primary completion date is Aug 2020 [4].
Jun 18First patient commences dosing in PIII OSTRO trial (NCT03401229). 400 patients will be recruruited from 8 countries comparing benralizumab 30mg every 8 weeks with placebo over 56 weeks. Primary outcome is nasal polyp burden and patient-reported nasal blockage. Data anticipated 2020 [1].

Evidence based evaluations

FasenraEosinophilic oesophagitis in patients aged 12 years and older

Information

Fasenra
Licence extension / variation
AstraZeneca
MedImmune

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Monoclonal antibody binding to the interleukin-5 receptor that depletes eosinophils
In 2013, eosinophilic oesophagitis was considered to affect less than 5 in 10,000 people in the EU [1]. Studies suggest that the prevalence is rising, but it is uncertain whether this is a true increase or due to better diagnosis; it is most common in middle-aged men [2].
Eosinophilic oesophagitis in patients aged 12 years and older
Subcutaneous injection

FasenraEosinophilic granulomatosis with polyangiitis

Information

Fasenra
Licence extension / variation
AstraZeneca
MedImmune

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Fully humanised IgG monoclonal antibody specific for interleukin 5 (IL-5)
Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss Syndrome, is an inflammatory disease of small and medium sized blood vessels. The lungs and skin are commonly affected but it can affect other organs including the heart, kidneys, nerves and bowels. EGPA seems to affect men and women equally. Around 11-13 people per million are diagnosed with EGPA [1].
Eosinophilic granulomatosis with polyangiitis
Subcutaneous injection

FasenraChronic obstructive pulmonary disease (COPD)

Information

Fasenra
Licence extension / variation
AstraZeneca
MedImmune

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Monoclonal antibody binding to the interleukin-5 receptor that depletes eosinophils
An estimated three million people are affected by COPD in the UK. About 900,000 have been diagnosed with COPD and an estimated two million people have COPD which remains undiagnosed. The rate of COPD in the population is estimated at between 2% and 4%. The diagnosed prevalence of COPD is 1.5%. The prevalence increases with age, with an estimated prevalence of 10% in men older than 75.
Chronic obstructive pulmonary disease (COPD)
Subcutaneous

Evidence based evaluations